Question 1

What is Deucrictibant?

Accepted Answer

Deucrictibant is a Other.

Question 2

How often does Deucrictibant appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Deucrictibant first tracked by Ergen?

Accepted Answer

First tracked on May 29, 2026.

Question 4

When was Deucrictibant last mentioned in news?

Accepted Answer

Last active on May 29, 2026.

Question 5

What is Deucrictibant's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Deucrictibant in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Deucrictibant?

Accepted Answer

Pharvaris Presents Deucrictibant Clinical Data (May 29, 2026, 8 articles).

Question 8

How did the "Pharvaris Presents Deucrictibant Clinical Data" event impact Deucrictibant?

Accepted Answer

Deucrictibant is the novel oral drug developed by Pharvaris, with clinical data being presented for its use in treating hereditary angioedema and acquired angioedema.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.